Skip to main content

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Primärliteratur

  1. De Vita VT, Carbone PP, Owens AH, et al: Clinical trials with 1,3-bis(2chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25: 1876–1881, 1965.

    PubMed  Google Scholar 

  2. Marsh JC, DeConti RC, Hubbard SP: Treatment of Hodgkin’s disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC409962). Cancer Chemother Rep 55: 599–606, 1971.

    PubMed  CAS  Google Scholar 

  3. Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.

    Article  PubMed  CAS  Google Scholar 

  4. Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.

    PubMed  CAS  Google Scholar 

  5. Colvin M, Hartner J, Summerfield M: Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 37: 677–678, 1980.

    PubMed  CAS  Google Scholar 

  6. Laskar PA, Ayres JW: Degradation of carmustine in aqueous media. J Pharm Sci 66: 1073–1076, 1977.

    Google Scholar 

  7. Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.

    Article  CAS  Google Scholar 

  8. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  9. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  10. Allwood M: Chemotherapeutic agents: carmustine. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 199–202, 1997.

    Google Scholar 

  11. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton * Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  12. Dorr RT, Von Hoff DD: Drug monographs: carmustine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton * Lange, 2nd edition: 267–275, 1994.

    Google Scholar 

  13. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Fachinformation Carmubris® (Österreich), Bristol-Myers Squibb, Juli 1996.

    Google Scholar 

  15. Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.

    Google Scholar 

  16. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  17. Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.

    PubMed  CAS  Google Scholar 

  18. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  19. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.

    Google Scholar 

  20. Donislawski S, Gain M, Meyer-Jürshof A, et al: Carmustin: Behandlung von Paravasaten. In: Donislawski S, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 2: 21, 1994.

    Google Scholar 

  21. Holmes BC: Administration of cancer chemotherapy agents. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton * Lange, 2nd edition: 57–94, 1994.

    Google Scholar 

  22. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.

    Google Scholar 

  23. Barth J: Paravasate und deren Behandlung. In: Barth J (Hrsg) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, Kap. VI-3: 1–9, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). Carmustin. In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3799-4_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3800-7

  • Online ISBN: 978-3-7091-3799-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics